[go: up one dir, main page]

RU2012124063A - MEDICINAL COMBINATION WITH THEOBROMIN AND ITS USE IN TREATMENT - Google Patents

MEDICINAL COMBINATION WITH THEOBROMIN AND ITS USE IN TREATMENT Download PDF

Info

Publication number
RU2012124063A
RU2012124063A RU2012124063/15A RU2012124063A RU2012124063A RU 2012124063 A RU2012124063 A RU 2012124063A RU 2012124063/15 A RU2012124063/15 A RU 2012124063/15A RU 2012124063 A RU2012124063 A RU 2012124063A RU 2012124063 A RU2012124063 A RU 2012124063A
Authority
RU
Russia
Prior art keywords
opiate
codeine
noscapine
theobromine
administered
Prior art date
Application number
RU2012124063/15A
Other languages
Russian (ru)
Other versions
RU2587329C2 (en
Inventor
Джон Брю
Робин Марк Баннистер
Original Assignee
Байокоупи Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Байокоупи Лимитед filed Critical Байокоупи Лимитед
Publication of RU2012124063A publication Critical patent/RU2012124063A/en
Application granted granted Critical
Publication of RU2587329C2 publication Critical patent/RU2587329C2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

1. Средство (медикамент), содержащее теобромин и опиат, в виде комбинированного препарата для применения в терапии.2. Средство по п.1, где терапия является лечением кашля.3. Средство по п.1 или 2, в котором опиат выбран из кодеина, морфина, диаморфина, тебаина, папаверина, носкапина, орипавина, фентанила, альфаметилфентанила, алфентанила, суфентанила, ремифентанила, карфентанила, пропоксифена, оксиморфона, оксикодона, гидроморфона, петидина, дигидрокодеина, бупренорфина, эторфина, этилморфина, лоперамида и гидрокодона, пентазоцина, трамадола, типепидина и носкапина.4. Средство по любому из пп.1 или 2, в котором опиатом является кодеин.5. Средство или теобромин по любому из пп.1 или 2, в котором опиат вводится в дозе от 0,1 до 30 мг/кг/сут.6. Средство по п.4, в котором кодеин вводится в дозе до 3 мг/кг/сут.7. Применение теобромина в сочетании с опиатом для лечения кашля.8. Применение по п.7, где опиат выбран из кодеина, морфина, диаморфина, тебаина, папаверина, носкапина, орипавина, фентанила, альфаметилфентанила, алфентанила, суфентанила, ремифентанила, карфентанила, пропоксифена, оксиморфона, оксикодона, гидроморфона, петидина, дигидрокодеина, бупренорфина, эторфина, этилморфина, лоперамида и гидрокодона, пентазоцина, трамадола, типепидина и носкапина.9. Применение по п.7, где опиатом является кодеин.10. Применение по п.8, где опиат вводится в дозе от 0,1 до 30 мг/кг/сут.11. Применение по п.9, где кодеин вводится в дозе до 3 мг/кг/сут.12. Применение теобромина по п.7, для одновременного или последовательного применения с опиатом.13. Применение теобромина в комбинации с опиатом для получения средства для лечения кашля.14. Применение по п.13, где опиат выбр�1. An agent (medication) containing theobromine and opiate, in the form of a combined preparation for use in therapy. 2. The agent of claim 1, wherein the therapy is a cough treatment. The agent according to claim 1 or 2, wherein the opiate is selected from codeine, morphine, diamorphine, thebaine, papaverine, noscapine, oripavine, fentanyl, alfamethylfentanyl, alfentanil, sufentanil, remifentanil, carfentanil, propoxyphene, oxymorphone, oxydinodiodinone, oxydodiodone , buprenorphine, etorphine, ethylmorphine, loperamide and hydrocodone, pentazocine, tramadol, typeepidine and noscapine. 4. The drug according to any one of claims 1 or 2, wherein the opiate is codeine. 5. The agent or theobromine according to any one of claims 1 or 2, wherein the opiate is administered at a dose of 0.1 to 30 mg / kg / day. The tool according to claim 4, in which codeine is administered at a dose of up to 3 mg / kg / day. Use of theobromine in combination with an opiate for the treatment of cough. 8. The use according to claim 7, wherein the opiate is selected from codeine, morphine, diamorphine, thebaine, papaverine, noscapine, oripavine, fentanyl, alfamethylfentanyl, alfentanil, sufentanil, remifentanil, carfentanil, propoxyphene, oxymorphon, oxycodidonefenodorodinodinorodinodinorodinodinafedrodinafedina, hydrodinodinodinodinodin etorphine, ethylmorphine, loperamide and hydrocodone, pentazocine, tramadol, tipepidine and noscapine. 9. The use of claim 7, wherein the opiate is codeine. The use of claim 8, wherein the opiate is administered in a dose of 0.1 to 30 mg / kg / day. The use of claim 9, wherein codeine is administered at a dose of up to 3 mg / kg / day. The use of theobromine according to claim 7, for simultaneous or sequential use with an opiate. Use of theobromine in combination with an opiate to obtain a cough treatment. 14. The use of claim 13, wherein the opiate is selected�

Claims (15)

1. Средство (медикамент), содержащее теобромин и опиат, в виде комбинированного препарата для применения в терапии.1. The tool (medication) containing theobromine and opiate, in the form of a combined preparation for use in therapy. 2. Средство по п.1, где терапия является лечением кашля.2. The tool according to claim 1, where the therapy is a cough treatment. 3. Средство по п.1 или 2, в котором опиат выбран из кодеина, морфина, диаморфина, тебаина, папаверина, носкапина, орипавина, фентанила, альфаметилфентанила, алфентанила, суфентанила, ремифентанила, карфентанила, пропоксифена, оксиморфона, оксикодона, гидроморфона, петидина, дигидрокодеина, бупренорфина, эторфина, этилморфина, лоперамида и гидрокодона, пентазоцина, трамадола, типепидина и носкапина. 3. The tool according to claim 1 or 2, in which the opiate is selected from codeine, morphine, diamorphine, thebaine, papaverine, noscapine, oripavine, fentanyl, alfamethylfentanyl, alfentanil, sufentanil, remifentanil, carfentanil, propoxyphene, oxymorphone hydroformin, oxycodone, oxycodone, oxycodone, oxycodone, oxycodone , dihydrocodeine, buprenorphine, ethorphine, ethylmorphine, loperamide and hydrocodone, pentazocine, tramadol, typeepidine and noscapine. 4. Средство по любому из пп.1 или 2, в котором опиатом является кодеин.4. The tool according to any one of claims 1 or 2, in which the opiate is codeine. 5. Средство или теобромин по любому из пп.1 или 2, в котором опиат вводится в дозе от 0,1 до 30 мг/кг/сут.5. The tool or theobromine according to any one of claims 1 or 2, in which the opiate is administered in a dose of from 0.1 to 30 mg / kg / day. 6. Средство по п.4, в котором кодеин вводится в дозе до 3 мг/кг/сут.6. The tool according to claim 4, in which codeine is administered at a dose of up to 3 mg / kg / day. 7. Применение теобромина в сочетании с опиатом для лечения кашля.7. Theobromine in combination with an opiate for the treatment of cough. 8. Применение по п.7, где опиат выбран из кодеина, морфина, диаморфина, тебаина, папаверина, носкапина, орипавина, фентанила, альфаметилфентанила, алфентанила, суфентанила, ремифентанила, карфентанила, пропоксифена, оксиморфона, оксикодона, гидроморфона, петидина, дигидрокодеина, бупренорфина, эторфина, этилморфина, лоперамида и гидрокодона, пентазоцина, трамадола, типепидина и носкапина.8. The use according to claim 7, where the opiate is selected from codeine, morphine, diamorphine, thebaine, papaverine, noscapine, oripavine, fentanyl, alfamethylfentanyl, alfentanil, sufentanil, remifentanil, carfentanil, propoxyphene, oxymorphone, oxycodone, hydroxydodone, petromide, hydromide buprenorphine, etorphine, ethylmorphine, loperamide and hydrocodone, pentazocine, tramadol, tipepidine and noscapine. 9. Применение по п.7, где опиатом является кодеин.9. The use of claim 7, wherein the opiate is codeine. 10. Применение по п.8, где опиат вводится в дозе от 0,1 до 30 мг/кг/сут.10. The use of claim 8, where the opiate is administered in a dose of from 0.1 to 30 mg / kg / day. 11. Применение по п.9, где кодеин вводится в дозе до 3 мг/кг/сут.11. The use according to claim 9, where codeine is administered at a dose of up to 3 mg / kg / day. 12. Применение теобромина по п.7, для одновременного или последовательного применения с опиатом.12. The use of theobromine according to claim 7, for simultaneous or sequential use with an opiate. 13. Применение теобромина в комбинации с опиатом для получения средства для лечения кашля.13. The use of theobromine in combination with an opiate to obtain a cough treatment agent. 14. Применение по п.13, где опиат выбран из кодеина, морфина, диаморфина, тебаина, папаверина, носкапина, орипавина, фентанила, альфаметилфентанила, алфентанила, суфентанила, ремифентанила, карфентанила, пропоксифена, оксиморфона, оксикодона, гидроморфона, петидина, дигидрокодеина, бупренорфина, эторфина, этилморфина, лоперамида и гидрокодона, пентазоцина, трамадола, типепидина и носкапина. 14. The use according to claim 13, wherein the opiate is selected from codeine, morphine, diamorphine, thebaine, papaverine, noscapine, oripavine, fentanyl, alfamethylfentanyl, alfentanil, sufentanil, remifentanil, carfentanil, propoxyphene, oxymorphone, oxycodone, hydroxydodone, petromide, hydromide buprenorphine, etorphine, ethylmorphine, loperamide and hydrocodone, pentazocine, tramadol, tipepidine and noscapine. 15. Применение по п.13, в котором опиатом является кодеин. 15. The application of item 13, in which the opiate is codeine.
RU2012124063/15A 2009-11-13 2010-11-12 Drug combination with theobromine and use thereof in treatment RU2587329C2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0919893.8A GB0919893D0 (en) 2009-11-13 2009-11-13 Drug composition and its use in therapy
GB0919893.8 2009-11-13
PCT/GB2010/051896 WO2011058374A1 (en) 2009-11-13 2010-11-12 Drug combination with theobromine and its use in therapy

Publications (2)

Publication Number Publication Date
RU2012124063A true RU2012124063A (en) 2013-12-20
RU2587329C2 RU2587329C2 (en) 2016-06-20

Family

ID=41509327

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2012124063/15A RU2587329C2 (en) 2009-11-13 2010-11-12 Drug combination with theobromine and use thereof in treatment

Country Status (19)

Country Link
EP (1) EP2498776A1 (en)
JP (2) JP2013510842A (en)
CN (1) CN102740853B (en)
AU (1) AU2010317668C1 (en)
BR (1) BR112012011224A2 (en)
CA (1) CA2780704C (en)
CO (1) CO6551745A2 (en)
EC (2) ECSP12011892A (en)
GB (1) GB0919893D0 (en)
IL (1) IL219769A0 (en)
MX (1) MX2012005538A (en)
NZ (1) NZ599957A (en)
PE (1) PE20121472A1 (en)
PH (1) PH12012500955A1 (en)
RU (1) RU2587329C2 (en)
SG (1) SG10201407496SA (en)
UA (1) UA105940C2 (en)
WO (1) WO2011058374A1 (en)
ZA (1) ZA201204247B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9308211B2 (en) 2009-06-16 2016-04-12 Infirst Healthcare Limited Drug combinations and uses in treating a coughing condition
GB0910375D0 (en) 2009-06-16 2009-07-29 Biocopea Ltd Drug composition and its use in therapy
US9314465B2 (en) 2009-06-16 2016-04-19 Infirst Healthcare Limited Drug combinations and uses in treating a coughing condition
GB201111485D0 (en) * 2011-07-05 2011-08-17 Biocopea Ltd Drug composition and its use in therapy
US10016437B2 (en) 2009-06-16 2018-07-10 Infirst Healthcare Limited Drug combinations and uses in treating a coughing condition

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3850568D1 (en) * 1987-10-08 1994-08-11 Andor Bilas FABRIC MIXTURE TO STABILIZE THE METABOLISM LOCATION.
AU7604094A (en) * 1993-09-07 1995-03-27 Procter & Gamble Company, The Compositions containing an amino acid salt of propionic acid non-steroidal anti-inflammatory agent and at least one of a decongestant, an expectorant, an antihistamine and an antitussive
HUP9700654A2 (en) * 1997-03-26 1999-09-28 Dezső Korbonits Antitussive compositions containing theobromine
US6608073B1 (en) * 1998-10-14 2003-08-19 New Millennium Pharmaceutical Research, Inc. Intranasal codeine for the rapid suppression of cough and rapid relief of pain
HUP9802716A3 (en) * 1998-11-25 2000-08-28 Chinoin Gyogyszer Es Vegyeszet Pharmaceutical composition of analgesic activity
ES2528384T3 (en) * 2001-12-12 2015-02-09 The Government Of The United States Of America, As Represented By The Secretary Department Of Healt Methods of using adenosine receptor inhibitors to enhance the immune response and inflammation
CN1780605A (en) * 2003-02-28 2006-05-31 迪莱克斯治疗技术公司 Opioid drug delivery system
CN1593451A (en) * 2003-09-12 2005-03-16 杨喜鸿 Externally applied medicine for promoting male erection
EP1844792A4 (en) * 2004-12-14 2008-05-21 Shionogi & Co Therapeutic agent for constipation
US20080003280A1 (en) * 2006-06-26 2008-01-03 Levine Brian M Combination cough treatment compounds and method of treating common coughs
KR20080009994A (en) * 2006-07-25 2008-01-30 안국약품 주식회사 Cough Treatment Composition

Also Published As

Publication number Publication date
ECSP12011893A (en) 2012-10-30
AU2010317668C1 (en) 2016-02-11
SG10201407496SA (en) 2015-02-27
NZ599957A (en) 2014-05-30
MX2012005538A (en) 2012-09-28
CN102740853B (en) 2015-04-08
GB0919893D0 (en) 2009-12-30
AU2010317668B2 (en) 2015-01-22
WO2011058374A1 (en) 2011-05-19
CA2780704A1 (en) 2011-05-19
CA2780704C (en) 2018-07-17
ZA201204247B (en) 2013-02-27
CO6551745A2 (en) 2012-10-31
PE20121472A1 (en) 2012-11-30
RU2587329C2 (en) 2016-06-20
UA105940C2 (en) 2014-07-10
JP2013510842A (en) 2013-03-28
BR112012011224A2 (en) 2017-03-01
AU2010317668A1 (en) 2012-06-07
CN102740853A (en) 2012-10-17
EP2498776A1 (en) 2012-09-19
JP2016041748A (en) 2016-03-31
IL219769A0 (en) 2012-07-31
PH12012500955A1 (en) 2013-01-07
ECSP12011892A (en) 2012-09-28

Similar Documents

Publication Publication Date Title
NZ612837A (en) A combination of an opioid agonist and an opioid antagonist in the treatment of parkinson’s disease
JP2011519930A5 (en)
JP2010189403A5 (en)
WO2004045551A3 (en) Pharmaceutical composition
JP2011126895A5 (en)
JP2006524261A5 (en)
RU2009125597A (en) MEDICINES AND METHODS FOR PRODUCING AND USING THEM
CA2547334A1 (en) Methods and compositions for deterring abuse of opioid containing dosage forms
JP2013541567A5 (en)
JP2011515495A5 (en)
RU2007139827A (en) PHARMACEUTICAL COMPOSITIONS FOR PAIN TREATMENT
AR092820A1 (en) SYSTEMS AND METHODS TO TREAT AN ADVERSE ADVERSE PHARMACODYNAMIC RESPONSE, DOSE UNIT, KIT
JP2014088422A5 (en)
AR077394A1 (en) METHODS TO TREAT NVPA YNVPO WITH LONG-RELEASE ONDANSETRON COMPOSITIONS
JP2012519675A5 (en)
JP2009167214A5 (en)
JP2010511683A5 (en)
RU2013126476A (en) TREATMENT OF DEPENDENCE AND DISORDERS OF REASONS WITH APPLICATION OF PDE7 INHIBITORS
AR039336A1 (en) TRANSDERMAL ANALGESIC SYSTEMS WITH REDUCED ABUSE POTENTIAL
AR095160A1 (en) ALTERATION PROOF PHARMACEUTICAL FORMULATIONS
JP2009529046A5 (en)
JP2011137020A5 (en)
RU2012124063A (en) MEDICINAL COMBINATION WITH THEOBROMIN AND ITS USE IN TREATMENT
NZ619408A (en) Compositions and methods for prophylaxis and treatment of addictions
NZ603170A (en) Combination of active loaded granules with additional actives

Legal Events

Date Code Title Description
HZ9A Changing address for correspondence with an applicant
MM4A The patent is invalid due to non-payment of fees

Effective date: 20171113